News

Date Title
October 12, 2017
NEW YORK (GenomeWeb) – Stakeholders in the liquid biopsy field gathered yesterday to discuss the state of the science for blood-based cancer genomics, to quantify the challenges facing test developers and regulators, and to discuss ongoing projects and new data.
August 22, 2017
To ensure the accuracy of patient testing results, clinical next-generation sequencing (NGS) labs must track metrics across their assay’s workflow to determine whether runs were within established limits. Without software to help manage this data, labs must manually compile and trend data to determine whether a run passed or failed, introducing the possibility of transcription errors and adding to the turnaround time for patient results.
August 1, 2017
SeraCare Life Sciences, Milford, Mass, has launched Seraseq Circulating Tumor DNA v2 reference materials, aimed to closely mimic the performance attributes of ctDNA derived from clinical specimens.
July 24, 2017
NEW YORK (GenomeWeb) – As liquid biopsy genetic tests have rocketed into clinical practice over the last handful of years, clinical researchers, test developers, and others have begun to pay increasing attention to a relative lack of tools to ensure assays are validated and performed according to common, or at least equivalent standards
July 18, 2017
The lack of adequate circulating tumour DNA reference materials for developing and measuring safe, accurate, and reproducible assays continues to be a challenge for clinical labs.
June 28, 2017
Clinical labs are adopting next-generation sequencing technology at ever increasing rates. As sequencing costs decrease and the clinical utility of many applications increase, labs are rushing to implement clinical sequencing assays in part to keep critical patient testing volumes for cancer and inherited disease testing from leaving their networks.
June 5, 2017
Research presented at ASM Microbe 2017 by experts at the Fertility and Cryogenics Lab shows a reliable clinical assay that can detect the Zika virus from semen samples. "This assay can help reduce Zika infection rates and allow couples who are identified at risk due to travel or geographic location plan their pregnancy," said lead author Hisham Greiss M.D., Ph.D., HCLD at the Fertility and Cryogenics Lab.
June 4, 2017
New Orleans, LA – June 4, 2017 –Research presented at ASM Microbe 2017 by experts at the Fertility and Cryogenics Lab shows a reliable clinical assay that can detect the Zika virus from semen samples. “This assay can help reduce Zika infection rates and allow couples who are identified at risk due to travel or geographic location plan their pregnancy,” said lead author Hisham Greiss M.D., Ph.D., HCLD at the Fertility and Cryogenics Lab. A total of 100 semen samples were spiked with a recombinant Accuplex ZIKV (SeraCare Life Sciences) at 5 viral copies per ml and processed in Aptima Urine Transport medium (Hologic Inc.) and tested using Aptima® ZIKV assay released under the FDA’s emergency use authorization on the fully automated Panther system from Hologic, Inc. The samples were also tested for West Nile Virus, Chagas and Dengue, recombinant Dengue Virus, recombinant Chikungunya Virus, Human Papilloma Virus, Herpes Simplex Virus 1, Herpes Simplex Virus 2, Chlamydia, and Gonorrhea. The experiment was repeated three times and in triplicates each time.